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A recombinant plasmid containing expression units for human pre-interleukin 2 (pre-IL-2) and the select- 
able marker mouse DHFR, was constructed and used to transform DHFR- CHO cells to the DHFR+ 
phenotype. Selected colonies were isolated and tested for IL-2 production. Twelve highly IL-2-producing 
clones were amplified in stepwise increasing concentrations of methotrexate. The IL-2 secreted into the cul- 
ture medium by one of these clones was purified to homogeneity and partially characterized. N-terminal 
sequence analysis showed that pre-IL-2 was correctly processed during secretion. SDS gel electrophoresis 
and chromatofocusing experiments in conjunction with neuraminidase treatment indicated a posttranslatio- 
nal glycosylation of the secreted mature protein similar to that described for the tetrasaccharide structure 
of the N2 form of natural IL-2. This recombinant IL-2 has a specific activity of 2.5 x 10’ U/mg. 
Glycoprotein; Interleukin 2; Recombinant lymphokine 
1. INTRODUCTION 
Interleukin 2 (IL-2) is a lymphokine produced by 
T-cells after stimulation by mitogens or antigens 
[l]. This molecule is a key mediator of the growth 
and functional activity of B- and T-cells and 
cytotoxic cells including NK and LAK cells [2]. 
IL-2 has been purified from normal human lym- 
phocyte conditioned medium [3] and from the 
human lymphoblastoid cell line Jurkat [4]. Several 
forms were isolated and characterized as being 
variations in the glycosylation of the same 
polypeptidic backbone [5]. The importance of 
these posttranslational modifications in the in vivo 
activity of the molecule is still unclear [6,7]. 
Several groups have cloned and expressed the 
cDNA coding for IL-2 in E. coli obtaining large 
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amounts of unglycosylated IL-2 [8-IO]. Because 
of their capacity to glycosylate proteins recombi- 
nant eukaryotic systems have also been explored. 
Infected insect cells that correctly processed pre- 
IL-2 during secretion, however, were not able to 
glycosylate the molecule [ 1 I]. Recently, the pro- 
duction of rIL-2 by transfected mouse L cells and 
Chinese hamster ovary (CHO) cells was reported, 
and in vivo radiolabeling of the rIL-2 produced in- 
dicated that those systems could be used as sources 
of glycosylated rIL-2 [12]. 
Here, we describe an efficient system for the 
production of rIL-2 based on transformed CHO 
cells that correctly secrete large amounts of the 
matured recombinant protein into the culture 
medium. Partial characterization of this recombi- 
nant protein indicated a glycosylation pattern 
similar to the tetrasaccharide glycosylated human 
IL-2 [5]. The availability of large quantities of this 
rIL-2 may help in understanding the importance of 
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this modification on the structure and biological amethopterin, Sigma]: 0.02, 0.05, 0.1 and 0.2 PM 
effects of the molecule. MTX [17]. 
2. MATERIALS AND METHODS 
2.3. Production and purification of recombinant 
IL-2 
2.1. Plasmid construction 
The plasmid pSV 700 was constructed, contain- 
ing the SV40 early promoter, the coding sequence 
for human pre-IL-2 isolated from phytohemag- 
glutinin A-stimulated human peripheral lym- 
phocytes and identical to that previously published 
[13], the second intron of the mouse globin gene 
[ 141, and the SV40 early polyadenylation signal. 
The sequence between Hind111 and DdeI was 
replaced by a synthetic oligonucleotide sequence 
giving rise to the sequence ‘CCACCATGGCT in- 
stead of CCACAATGTAC around the initiator 
ATG (plasmid pSV 703). A third plasmid contain- 
ing both the expression units for human IL-2 (from 
pSV 703) and for the selectable marker mouse 
DHFR (from pSV2-DHFR [ 151) was constructed 
and termed pSV 720. The constructions are out- 
lined in fig.1. 
2.2. Cell culture, DNA transformation and 
amplification 
Transient expression assays were performed as 
in [16]. A DHFR-deficient CHO cell line [ 171 was 
propagated in a-medium (Gibco) supplemented 
with 10% fetal calf serum (FCS, Gibco), 20 pg/ml 
gentamycin, 60pg/ml tylocine and 300 pug/ml L- 
glutamine (non-selective medium). 
Recombinant IL-2 was obtained in suspension 
culture in spinner flasks using suspension medium 
(Gibco) with 5% FCS, 0.2pM MTX and 
150pg/ml proline. 1 1 of the culture supernatant 
was acidified to pH 4.5 with acetic acid and ap- 
plied directly to an S-fast flow Sepharose (Phar- 
macia) column (2.5 x 40.0 cm) previously 
equilibrated in 0.05 M ammonium acetate (pH 
4.5). After loading the sample, the column was 
washed with 0.05 M ammonium acetate (pH 5.5), 
0.05 M NaCl, followed by the same buffer con- 
taining 0.5 M NaCl. Biologically active IL-2 con- 
taining fractions were loaded on an Altex RP C3 
column (1 .O x 25.0 cm) and eluted with a gradient 
of acetonitrile in water, 0.1% trifluoroacetic acid 
(TFA), from 5 to 30% in 10 min, from 30 to 50% 
in 60 min and from 50 to 100% in 10 min at a flow 
rate of 4 ml/min. rIL-2 was finally chromato- 
graphed on an Altex RP Cl8 column (2.1 x 
10 cm). Fractions with IL-2 activity were analysed 
on SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) carried out according to Laemmli [20]. 
Proteins were visualized by silver staining (Bio Rad 
kit) of the gels. 
2.4. Amino acid composition and sequence 
analysis 
The DHFR- CHO cells were transformed to the 
DHFR+ phenotype with 1Opg plasmid pSV 720 
per 10 cm dish, using the calcium phosphate 
precipitation method [ 181 and omitting salmon 
sperm DNA as a carrier. After growth for 3 days 
in non-selective medium, cells were subcultured at 
a density of lo5 cells per 10 cm dish in selective 
medium: Eagle’s minimum essential medium (with 
Earle’s salts, Gibco), containing 10% dialyzed 
FCS (Gibco), 20 fig/ml gentamycin, 60 pug/ml 
tylocine (Gibco), 300 pg/ml L-glutamine and 
150 pug/ml L-proline. The selective medium was 
changed every 3 days and after 2 weeks, transform- 
ed colonies were isolated. 
Samples were dried in borosilicate tubes, 
hydrolyzed with gaseous HCl and analysed as 
described [21]. For N-terminal sequence analysis 
purified unmodified IL-2 was loaded onto a 
polybrene-coated filter and automatically se- 
quenced with a gas-phase protein sequencer equip- 
ped with an on-line phenylthiohydantoin-amino 
acid separation system (470A and 130A, Applied 
Biosystems, Foster City, CA). 
2.5. Neuraminidase treatment and chromato- 
focusing analysis 
In order to amplify the IL-2 and DHFR expres- 
sion units, initial transformants were grown in 
selective medium containing progressively increas- 
ing concentrations of methotrexate [MTX, (+)- 
rIL-2 was incubated with 1.5 U/ml of 1/. 
cholerae neuraminidase (Calbiochem) for 4 h at 
37°C as in [22], and analysed on a Mono P 
chromatofocusing column (Pharmacia) 
equilibrated in 25 mM Tris-HCl, pH 8.5, 0.1% 
polyethylene glycol and eluted with polybuffer 96 
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(Pharmacia)/water (I :20), pH 5.5, 0.1% 
polyethylene glycol at a flow rate of 1 ml/min. 
Fractions of 1 ml were collected and analysed for 
IL-2 activity. 
2.6. IL-2 biological assay 
The calorimetric assay of Mosmann [23] was 
used to determine IL-2 biological activity in the 
proliferation assay of the IL-2-dependent murine 
cytotoxic T-lymphocyte line CTLL-2 [24]. IL-2 
units were referred to the BRMP-Standard 
Reference Reagent Preparation [25]. 
3. RESULTS 
3.1. Isolation of highly productive IL-2 cell lines 
The plasmid pSV 700 directed the synthesis of 
pre-IL-2 and secretion of IL-2 into the culture 
medium. To increase the efficiency of this plasmid 
the sequence surrounding the initiator ATG was 
changed to conform with the consensus sequence 
CCACC-ATG-G as described by Kozak [26]. As 
a result the second amino acid of pre-IL-2, 
tyrosine, was changed to alanine. This new 
plasmid, pSV 703, was more efficient than the 
parental plasmid pSV 700 when tested for transient 
expression (not shown). The plasmid pSV 720 con- 
tains both the expression unit for pre-IL-2 from 
pSV 703 and that for mouse DHFR. 
CHO-DHFR- cells were transformed with the 
plasmid pSV 720 (fig. 1) and subsequently cultured 
in selective medium. 81 colonies were isolated and 
tested for their capacity to secrete IL-2 into the 
culture medium; 78 of those colonies were found 
to be positive. 12 of the best producing clones (be- 
tween 1 and 3 x lo4 IL-2 units accumulated per 
dish, in 5 days, with initially 5 x lo5 cells per dish) 
were subjected to increasing MTX concentrations 
and several highly productive cell lines were ob- 
tained; one of those, clone 32, was used for further 
studies. Clone 32 (5 x lo5 cells), seeded in a 6 cm 
dish with selective medium containing 0.1 PM 
MTX and cultured for 5 days, produced 2.5 x 
lo5 U vs 1 x lo4 U before amplification. 
3.2. Purification and chemical analysis of rIL-2 
Recombinant IL-2 was usually purified from 1 1 
suspension culture of recombinant CHO clone 32. 
The rIL-2 was initially concentrated and partially 
purified by ion-exchange chromatography on an S- 
Fig. 1. Construction of plasmid pSV 720 using the 
EcoRV-PvuI fragment of pSV 703, containing the 
expression unit for human pre-IL-2, and the PvuI-PvuII 
fragment of pSV2-DHFR, containing the selection unit. 
fast flow Sepharose column. Biologically active 
fractions eluted from this column were pooled and 
finally purified by two HPLC steps. The purity of 
rIL-2, as assessed from SDS-PAGE, was estimated 
to be greater than 95% (fig.2A). The overall 
purification yield was usually better than 40%. 
The amino acid composition of rIL-2 is in agree- 
ment with that derived from the cDNA and from 
previously purified natural IL-2 (not shown). 
Amino acid analysis was the procedure employed 
for protein quantitation when the specific activity 
of rIL-2 was determined. 
Sequence analysis of the purified material 
established that the first ten N-terminal residues of 
the molecule (table 1) are in agreement with the se- 
quence previously reported for the natural product 
[27]. Alanine is the only residue detected at the 
amino-terminus, thus showing that pre-IL-2 has 
been efficiently cleaved at the correct position dur- 
ing secretion. Less than 5% of the expected 
threonine was recovered in cycle 3 and no other 
PTH-amino acid was identified in this cycle. 
3.3. Neuraminidase treatment of rIL-2 
Freshly HPLC purified IL-2 shows two major 
bands on silver-stained SDS-PAGE of 17 and 
49 
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Fig.2. SDS-PAGE analysis of purified rIL-2 before (A) 
and after (B) neuraminidase treatment. Numbers (kDa) 
indicate the migration of known proteins. 
16.5 kDa, and a minor one of 15 kDa (fig.2A). 
Neuraminidase treatment of rIL-2 rapidly in- 
creased formation of the 15 kDa component 
Table 1 
N-terminal sequence of CHO-derived IL-2 
Cycle PTH-amino acid Yield (pmol) 
Expected Identified 
1 Ala Ala 
2 Pro Pro 
3 Thr X 
4 Ser Ser 
5 Ser Ser 
6 Ser Ser 
7 Thr Thr 
8 Lys Lys 
9 Lys Lys 
10 Thr Thr 
288.8 
235.0 
- 
47.7 
50.7 
42.4 
62.5 
103.4 
124.3 
60.9 
Initial yield, 58%; X, no PTH-amino acid identified 
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Fig.3. Chromatofocusing analysis of rIL-2 before (A) 
and after (B) neuraminidase treatment. 
(fig.2B) suggesting that covalently linked sialic 
acids are present in rIL-2 and responsible for the 
17 and 16.5 kDa forms. Complementary informa- 
tion was obtained by chromatofocusing ex- 
periments. The purified material shows two main 
forms of pZ 7.0 and 7.6. Biological activity in 
neuraminidase-treated material eluted from the 
column mainly with a pZ value of 8.0 (fig.3). 
4. DISCUSSION 
The isolation of CHO cell lines that are highly 
productive for human IL-2 allows an almost 
unlimited supply of this lymphokine with a struc- 
ture close to, or identical to, natural human IL-2 
to be made available. Production levels are at least 
two orders of magnitude higher than those ob- 
served after stimulation of human peripheral ym- 
phocytes and one order of magnitude greater than 
those obtained with highly productive cell lines 
derived from Jurkat [28]. The advantage of the 
CHO cell line described here is that the production 
of IL-2 is continuous and no stimulation is re- 
quired. The IL-2 production level obtained in this 
study, up to 5 x lo4 U/ml, compares favorably 
with those previously described, i.e. 2 x 10’ U/ml 
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for transformed CHO cells and 1.5 x lo3 U/ml for 
transformed L cells [ 121. 
rIL-2 was purified from culture medium via a 
simple and rapid procedure that combined cation- 
exchange chromatography and reverse-phase 
HPLC; SDS-PAGE analysis of purified rIL-2 
showed two major components of 17 and 
16.5 kDa, and a minor one of 15 kDa. The amino 
acid composition of rIL-2, consistent with that 
deduced from the cDNA, was used to calculate the 
concentration of purified material used for IL-2 
biological activity assay in a murine 
IL-Zdependent cytotoxic T-lymphocyte line. The 
specific activity of this rIL-2, related to the IL-2 
Reference Reagent Preparation obtained from the 
Biological Response Modifier’s Program, was 2.5 
x 10’ U/mg. In a comparative study of six human 
lymphoid and six recombinant IL-2 preparations, 
11 showed specific activities lower than 2.5 X 
10’ U/mg and one a specific activity greater than 
this value [29]. Other published specific activities 
for recombinant E. coli derived IL-2 are: 1.0 x 
10’ U/mg [30] and 0.4 x 10’ U/mg [7]. 
N-terminal sequence analysis showed that pre- 
IL-2 was correctly processed during secretion. The 
first 10 Edman degradation cycles yielded a single 
sequence identical to that expected from the cDNA 
except for cycle three, where the threonine gave 
non-quantitative recovery, suggesting post- 
transcriptional modification at this residue. This 
threonine has been described as the site of 
glycosylation in natural and Jurkat IL-2 [5,27]. 
Further information was obtained from 
chromatofocusing analysis of rIL-2 where two ma- 
jor forms eluted at pl values of 7.0 and 7.6. Treat- 
ment of rIL-2 with neuraminidase shifted the 
biological activity from pl 7.0 and 7.6 to pZ 8.0, 
and from 17 and 16.5 kDa to 15 kDa, indicating 
that heterogeneity is related to the presence of 
sialic acid in the molecule. 
These results show that this transformed CHO 
cell line is able to produce large quantities of an O- 
glycosylated IL-2 of 17 kDa and pZ 7.0. Similar 
properties have been described for one form of 
natural IL-2, N2, whose carbohydrate structure 
corresponds to o-NeuAc-(2-3)-P-D-Galp-(1-3)-[0- 
NeuAc-(2-6)]-D-GalNAc [5]. The rIL-2 of 16 kDa 
and pl 7.6 is assigned to a form similar to the 
natural monosialylated IL-2 N 1 [5]. This form may 
not be produced by the cells but, rather, may result 
from desialylation of the 17 kDa rIL-2 either in the 
culture medium and/or during purification, since 
storage of the culture medium before purification 
or storage of the purified IL-2 at 4°C in the acidic 
HPLC eluting buffer resulted in an increased pro- 
portion of the 16 kDa form and occasionally also 
in the production of a 15 kDa form (not shown). 
This study shows that large amounts of IL-2 can 
be obtained by recombinant plasmid transformed 
CHO cells without obvious alteration of the 
natural glycosylation pattern. Recently, Pawelec et 
al. [7] stressed the importance of the glycosylation 
based on the observation that natural IL-2, a mix- 
ture of three different glycosylated molecules, was 
more effective than E. co/i-derived IL-2 in the sup- 
port of the clonal outgrowth of human T-cells. 
Current work in our laboratory is directed at the 
full characterization of this CHO-derived rIL-2 
and at exploring in detail the biological role of O- 
glycosylation in the half-life and in vivo effects of 
the molecule. 
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